avesthagen final

India’s leading integrated systemsbiology platform company

focus

convergence between food, pharma and population genetics

develop products forpredictive, preventive and personalized healthcare

EthosAVESTHAGEN LIMITED

HealthcareNutrition

Business Model | Product Strategy

Systems Biology

Predictive Preventive

Personalized

bioNutrition bioAgriculturebioPharmaceuticals

Technologies | Products

AVESTHAGEN LIMITED

Business Model | Alliances Strategy

bio

Nu

trit

ion

bio

Ag

ricu

ltu

re

bio

Ph

arm

ace

uti

cals

Alliances

AVESTHAGEN LIMITED

Avesthagen Platform

Early Research

Trials & Validation Production

bioNutrition

Early Research

Crop Development Trials Regulatory

bioAgriculture

Product Development

Partner(s)

Marketing

Marketing

Subsidiary(ies)Avesthagen

Lab Scale

Process Development

API Production

Regulatory Approvals

bioPharmaceuticalsMarketing

Business Model | Growth through PartnershipAVESTHAGEN LIMITED

Biomarker Discovery

pDx + PVx + PRx*

2008 2010+ 2015+

- pDx + Fx - pDx + Rx

Nutrigenomics pDx + PFx + PRx

Clinically Validated Bioactives (Fx)

* Includes biopharmaceuticals and bioactives products

pDx + PVx + Rx

Predictive / Preventive (p)

bioNutrition

Personalized (P)

AVESTAGENOMEPredictive Diagnostics (pDx)

bioPharmaceuticals

Business Model | Product Development StrategyAVESTHAGEN LIMITED

Group Structure | Global FootprintAVESTHAGEN LIMITED

Group Structure | ShareholdingAVESTHAGEN LIMITED

Dr. Villoo Morawala-PatellChairperson

Founder and Managing Director, AVESTHAGEN LIMITED

Mr. Darius E. UdwadiaVice Chairman

Founding partner of Udwadia & Udeshi, Solicitors & Advocates

Mr. Emmanuel Rougier

Directors

Deputy CEO, Groupe Limagrain

Mr. Jochen Ebert Managing Director, Danone India Pvt. Ltd.

Prof. Marc Van Montagu Founding Director of IPBO

Mr. Nadir Godrej Managing Director of Godrej Industries

Mr. K Ravindra Chief Risk Officer, ICICI Venture Fund

Mr. Koen Wentink Chief of Logistics, AVESTHAGEN LIMITED

Board of DirectorsAVESTHAGEN LIMITED

Dr. Helle Bechgaard Vice-Chairman, Dankse Bank, Denmark

Mrs. Farah Morawala-Patell-SochaInstitute of Biotechnology, Cambridge University

Ms. Sanaya Morawala-Patell Institute of Biochemistry, Cambridge University

Prof. Frank Gannon Director General, Science Foundation Ireland, Previously Director of EMBO

Dr. Robert L. Strausberg Deputy Director, J Craig Venter Institute

Prof. Satyajit Mayor Cellular Organisation & SignallingNational Centre for Biological Sciences

Prof. N.K. Ganguly Distinguished Biotechnology Fellow & AdvisorTranslational Health Science & Technology InstituteDepartment of Biotechnology, National Institute of Immunology

Scientific Advisory BoardAVESTHAGEN LIMITED

Prof Rita Colwell Distinguished Professor, University of Maryland,John Hopkins Institute of Public Health, Previously Director of the National Science Foundation, USA

Prof. G. Padmanabhan Honorary Professor, Department of BiochemistryIndian Institute of Science, Previously Director of IISc.

Dr. Sven Thormahlen Director General Danone Research

Dr. Chris Bowler Molecular Marine Biology, Ecole Normale Supérieure, Paris

Dr. Jean-Pierre Isal Independent Consultant (Previously Senior VP, Quintiles)

Dr. Villoo Morawala-Patell Founder and CMD

Mr. Samaresh Parida Chief Operating Officer

Mr. Bruce Murdoch Chief Business Officer

Mr. Supriyo Guha Company Secretary

Dr Rajesh Ullanat Chief Scientific Officer, bioPharmaceuticals

Dr Sami Guzder Chief Scientific Officer, Science & Innovation

Mr. Koen Wentink Chief Logistics Officer

Management Team

Dr Renuka Jain Chief Scientific Officer, BioNutrition

Mr. Pierre Socha Vice-President, Corporate Development

Dr. Anil Ram Chauhan Vice-President, Operations and Corporate Affairs

AVESTHAGEN LIMITED

Financial Investors

Strategic Investors

ICICI Ventures India

Fidelity International

Danone France

Limagrain France

Godrej Industries IndiabioMérieux France

Tata Industries India

Key Shareholders

Cipla India

New York Life USA

AVESTHAGEN LIMITED

180Inventions

bioPharma

MetabolicEngineering

bioAgriculture

bioNutrition

Diagnostics

IP PortfolioAVESTHAGEN LIMITED


Type of Application Indian USA EU Australia S. Africa Korea TotalPatents Granted 2 2 1 2 1 1 9

Group Inventions Application/FilingsbioAgriculture 46 74bioNutrition 75 145bioPharmaceuticals 13 98Science and Innovation 46 29TOTAL 180 346

Patents

Avesthagen has been granted 9 patents across different countries, the details of which is provided below. Additionally, a total of 346 patent applications are pending today in different jurisdictions.


Business AGT General bioNutrition bioAgriculture S&I Total

Copyrights Granted 1 3 1 2 7Copyright Applications 4 4 - - 8

Copyrights

7 copyrights have been granted, of which 5 are in India and 2 in the United States.

Another 8 copyright applications are pending.

The distribution of the copyrights across the business is given below.


Business AGT General bioNutrition bioAgriculture S&I bio Pharma Total

Trademarks Registered 5 40 1 - - 46Trademark Applications 17 23 6 2 1 49TOTAL 22 63 7 2 1 95

Trademarks

46 trademarks have been Registered and a further 49 trademark applications are pending in India. The distribution of these across the business is given below.

bioNutritionbioNutrition

Strategy & Product PipelineStrategy & Product Pipeline

Mission StatementbioNutrition

Global nutrition platform specializing in the discovery, development and marketing of branded and clinically validated plant based bioactives aimed at degenerative conditions.

In the near future, Avesthagen will bring new products for B2C and B2B markets developed in collaboration with private / public partners

With the convergence of Avestagenome and Drug Discovery efforts new personalised bioactives will be launched

Availability of extensive databases that include a widerange of products used in traditional systems of medicine practiced in India and SEA and a compendium of herbal medicines used across the world.

A proprietary methodology called MetaGridTM, which is based on the use of sophisticated high-throughput instrumental analysis.

Validation of the activity of compositions using tissue specific gene expression profiling (micro-arrays) and highly targeted cell and animal models of human diseases.

Strategy | Proprietary ToolsbioNutrition

ADePt TM

MetaGrid TM

Effective Clinical R&D model

MetaGridTM

Strategy | R&DbioNutrition

Strategy | Product PipelinebioNutrition

Diabetes

Clinical trials completed

Lowers Glycemic Index

Snacks

Pre-clinical trials completed

Insulin mimetic and sensitization activity

Beverage and snacks



Beverage and snacks

Govad Pre-clinical trials completed

Lowers Glycemic Index and Insulin sensitization

Snacks and beverages




Mohor Pre-clinical trials completed

Insulin sensitization Snacks and beverages

Teestar

ASPAND

Brand Name Status Functionality Food Application

Gosh

Health Condition

Strategy | Branded BioactivesbioNutrition

Bone Health


Promotes bone formation



Promotes bone formation

Snacks


Reduces bone resorption


Cardiovascular Health


Lowers cholesterol Beverages and Snacks

Antioxidant Clinical trials completed Cell rejuvination


Brand Name Status Functionality Food Application

Health Condition

Strategy | Branded BioactivesbioNutrition

2008 2010+ 2015+


Bioactives Abbreviated Trials

FFM

Foods

Nutraceuticals

Strategy | Product PositioningbioNutrition


Health Foods Abbreviated Trials

Rx Clinically Validated


OTC drugs Abbreviated Trials

Bioactives Clinically Validated

Functional Foods Clinically Validated

Discovery, development and marketing of branded therapeutic nutritional bioactives aimed at degenerative conditions, especially diabetes and weight management, CVD, osteoarthritis and osteoporosis, stress and cancer.

Joint product optimization and development

Joint testing and validation with marketing partner

Exclusive Manufacturing rights to Avesthagen

Marketing of product

Avesthagen entitled to royalties and milestone payments / success fees

Joint IP ownership

Business Model

Partner(s)Subsidiary(ies)

Avesthagen

Early Research

Trials & Validation Production

Product Development Marketing

bioNutrition

For specified product categories

bioNutrition

Strategy | B2B - Collaborations

Strategy | B2C - Functional FoodsbioNutrition

Functional Foods using active ingredients developed by Avesthagen (launch May 2008)

Muesli & Breakfast Cereals (7 variants)

Whole Wheat Crackers (6 variants)

Bars (4 variants)

Ethnic Snacks (end 2008)

Salient features

Reduces blood glucose levels

Maintains optimum body weight

100% Natural

Zero trans fat

Ideal ratios of SFA: MUFA: PUFA

Good source of dietary fibers

Prebiotic

Suitable for pre diabetics

Suitable for calorie conscious

No added artificial colours, flavors or preservatives

Approx. Nutrition facts (per 100g)

Energy

(kcals)

Carbs

(g)

Protein

(g)

Fat

(g)

Fiber

(g)

384.02 53 11.46 10 18.09

Recommended serving: 4-5 crackers twice a day

Whole Wheat Crackers – with TEESTAR™


Value Proposition

A healthy and natural treat, Good Earth Whole Wheat Crackers, are light, heart-friendly and easy to digest.

High Fibre content from wheat bran used in its original form.

Zero Trans fat which means lower blood cholesterol levels and reduced risk of cardiovascular problems.

An ideal healthy snack to be eaten at anytime of the day

Plain Wheat, Ground Garlic, Roasted Sesame, Crushed pepper, Flaked Chilli & Toasted Jeera


Whole Wheat Crackers


Breakfast Cereals

Good Earth Muesli Bars Value Proposition

On-the-go snack, keeps you going until your next meal.

Natural fruits and almonds provide micronutrients essential for maintaining good health.

High proteins from skimmed milk and soy protein repair damaged cells owing to intense physical activity

Presence of sugars and assimilated carbohydrates result in instant and sustained energy.

Available in three variants -, Apple Cinnamon , Cocoa Dates Almonds and Orange Peel Raisins Dates


Launched in US Market

Launch in India : mid 2008 EU Launch : end 2008

Strategy | B2C - OTCbioNutrition

Strategy | B2C - OTCbioNutrition

Fundamental changes in the dynamics of the healthcare industry are the driving growth of the nutrition industry :

An increasingly aging population

The increasing cost of healthcare

The growing trend towards self-medication

The growing consumer interest in alternatives to pharmaceuticals

Nutrition is being increasingly recognized as a major avenue for healthcare

Consumer is increasingly aware of the linkage between health and nutrition

The Dietary Supplement and Health and Education Act (DSHEA)

Market | Industry DynamicsbioNutrition

Cardio-vascularDiesease

Cancer Diabetes Over-weight& Obesity

OtherChronic

All Other TotalHealthcare

cost

$ Billions

Source: CDC, US Dept of Health & Human Services

33%

20%

11%

10%9%

17%100%

Cost Distribution by Disease State (2005)

74% of Total Costs

CVD Cancer Diabetes Obesity Other Chronic

All Other Total Healthcare

Cost

$653 $396 $226 $209 $190 $342 $2,016$ Billions

Market | “Big Four” Health ConditionsbioNutrition

Functional foods

The global market is estimated to be USD 85 billion in size in 2006, growing at a rate of 8-9% p.a. USA, Europe and Japan are the largest markets for functional foods.

Dietary supplements

The global market for dietary supplements is estimated at USD 68 billion (2006), and is exhibiting a growth rate of 4-5% per annum. The US is the largest market for dietary supplements, with an estimated market size of USD 22 bn.

Global functional ingredient sales

Global ingredient sales are estimated at USD 9.4 billion for 2006. This constitutes USD 7.6 bn. as supply to the supplement market, and USD 1.8 billion as supply to the functional food market.

Source: Nutrition Business Journal November 2007

MarketsbioNutrition

bioPharmaceuticals bioPharmaceuticals


Mission Statement

Strategy for biosimilars though partnering for cost effective healthcare focusing on mammalian blockbusters with high entry barrier.

In the near future, Avesthagen will bring new biopharma technologies and products developed in collaboration with private / public partners

With the convergence of Avestagenome and Drug Discovery efforts new personalised biopharmaceuticals will be launched

bioPharmaceuticals

Co-funded Development program for pipeline of Biosimilars with high entry barriers

Avesthagen responsible for development and manufacturing

Partner responsible for marketing of product

Avesthagen entitled to 20% royalties on net sales of the products

IP shared between partners equally

Manufacturing facilities for biologicals (being setup in India + Acquisition in Germany + dialogues on with other Asian countries)

Business Model


Avesthagen

Lab Scale

Process Development

API Production

Regulatory Approvals Marketing

bioPharmaceuticals

Product PipelinebioPharmaceuticals

RevenuesbioPharmaceuticals

cGMP facility, Bangalore, India

Phase 1 –Phase 1 – Setup of pilot scale manufacturing facility To be completed by third quarter 2008 Capacity 200 L bioreactor (2 low/medium dosage molecules) cGMP qualified facilities – 2 x 200 L & 1000 L (Germany and Malaysia)

Phase 2 –Phase 2 – Setup of large scale manufacturing facility Capacity – 10,000 lt bioreactor with DSP infrastructure Will be completed by late 2010 cGMP qualified Will be certified by the USFDA Acquisition of manufacturing plant

an option being investigated

cGMP facilityBerlin, Germany

Manufacturing | SitesbioPharmaceuticals

Bangalore PDLCell line DevelopmentProcess Development

2 Projects at a time

Bangalore GMPPre-clinical materialClinical material50L / 150LOne project

Berlin PDLCell line DevelopmentProcess Development

1 Project at a time (currently)

Kleinmachnow GMPPre-clinical materialClinical material50L / 200L(Two) projects at a time

Innobiologics PDLProcess Development

30LOne project

Innobiologics GMPPre-clinical materialClinical material30L / 300L / 1‘000LOne project

CMO1‘000 L

Indian Operations German Operations

Malaysian Operations3rd Party Operations

Manufacturing | Networking of project sitesbioPharmaceuticals

The Total world market for Biological products in 2007 was valued at Euros

60 billion and market value of the Biosimilar product portfolio is Euros 15

billion.

The Therapeutic segments that Avesthagen ‘s Biosimilar pipeline are

directed, which includes, Autoimmune disease, Cancer and Blood disorders

are valued at Euros 70 billion worldwide and INR 4 billion in India.

Market | Entry Strategy bioPharmaceuticals

AVESTHAGENBIOSIMILARS

2011 - 2018

EU/US/REGULATED

EUR 15 bil

BRIC MARKETS

EUR 2 bil

INDIAN MARKETS

EUR 600 mil

2010 - 2012

2009 - 2012

bioPharmaceuticals

Market | Entry Strategy

Market | Entry Strategy bioPharmaceuticals

The first products will be launched in India in 2009 and 2010 followed by

BRIC countries and then EU and USA once Patents begin to expire on the

products.

The Market entry strategy for India and BRIC countries is to market

through the largest Pharmaceutical company in India- Cipla Ltd (market

share of 6%.) Cipla will participate in Clinical Phases, Regulatory approval,

Formulation and Marketing. Revenue will come from API sales and

Royalties.

The Market entry strategy for EU, USA and Regulated markets is to

secure strong market partners early in the Clinical Development and

Regulatory process to market beginning 2011/12. Revenue will come from

Licensing, Milestones, API sales and Royalties.

Collaborations bioPharmaceuticals

Ongoing discussions

• Medium sized Pharma company based in Vienna, EU

• Large Biopharma company (No.2) based in EU

• Large Biopharma CMO and supplier based in Basel, EU

New discussions

• Large Pharma company moving into Biologics, US

Collaborations bioPharmaceuticals

bioAgriculturebioAgriculture


Mission Statement

Avesthagen Seed Promise: To build credibility with farmers and commitment to excellence while growing as a profitable enterprise.

To improve productivity in Agriculture and develop technologies that address global environmental challenges to achieve a sustainable future through a fine blend of food, feed, fibre and fuel.

bioAgriculture

Strategy | Market entry

bioAgriculture

Petroleum ApplicationsFuel, Oil Lubricants

Fibre ApplicationsEquipments, Clothing Construction

Industrial ApplicationsPlastics, Food Stuffs, Adhesives

2008 2010+ 2015+

Other Applications

Animal HusbandryNutrition / AdditivesFeeding / Sheltering

Environment Adjusted CropsNutrition-FITTM : DHA, ALA, LycopeneStress Resistance : Drought-FITTM, Salinity-FITTM

Hybrid-FITTM

Food & Feed

Development of Environment Adjusted plants for food, feed, fuel and fibre

Avesthagen takes ideas to proof-of-concept stage and partners for development of products

Joint green house testing and field validation with a) marketing partner or b) Atash Seeds Pvt Ltd (subsidiary)

Avesthagen entitled to licensing fees, milestone payments / success fees and royalties

Joint marketing of product

Joint IP ownership


Avesthagen

Business Model | Environment Adjusted CropsbioAgriculture

Early Research

Crop Development Trials Regulatory

Marketing

Market | Global Area of Biotech CropsbioAgriculture

Source : International

Seed Federation, 2008

Market | Domestic MarketsbioAgriculture

Field Crop Varieties Wheat, Rice and Peas

Field Crop Hybrids Rice, Cotton, maize, Sunflower, sorghum, pearl millet, and tur dal

Vegetable Hybrids Tomatto, Chilli, Brinjal, Cabbage, Cauliflower,

Beans, Gourds, Greens and Melons

bioAgriculture

Product Pipeline | 1st generation (Atash Seeds)

Public - Private Collaborations

Hybrid Pigeonpea (ICRISAT)Millet (ICRISAT)Drought Rice (UAS)

bioAgriculture

Product Pipeline | 2nd generation

Hybrid-FITHybrid-FITTMTM

Salinity-FITSalinity-FITTMTM

Drought-FIT Drought-FIT TMTM Nutrition-FITNutrition-FITTMTM

Rice

Tomato

Tomato

Rice

Pearl Millet

Rice

Sunflower

Mustard

Marker Assisted Marker Assisted Selection / Breeding Selection / Breeding

Bio-fuelsBio-fuels

Maize

Rice

Jatropha

Product Pipeline | 3rd generation

Barley

bioAgriculture

Nutrition-FITTM

High Anti oxidant Rice (Non GM)

Collection of over ninety lines Currently in field for multiplication Analysis for antioxidant content, 2008 Large scale cultivation, 2008 High antioxidant Rice based product, 2009 Market Launch Globally, 2009 Estimated rice production 2008, 423 Million Tons Coloured Rice Market Globally: Over 100 M USD

Product Pipeline | 3rd generationbioAgriculture

Nutrition-FITTM


High Lycopene Tomato

– Analysis for antioxidant content, 2007– A range of 250-500% increase in Lycopene– Currently analysing fruits of third generation– Selection of plant and tissue culture, 2008– Permission for Protected Cultivation trial, 2008– Large scale Greenhouse cultivation, 2009– High Lycopene tomato puree product development, 2009– GM Lycopene product development, 2009– Market Launch 2011– Market Size 2009 for lycopene sales will surpass $26 million,

according to Frost & Sullivan

Drought-FITTM


Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~2011 Multigene gene Indica rice (GM) ~ 2012

Drought-FITTM


Drought tolerant Indica Rice (MAB) Checked in All India Trials Best Material so identified for drought tolerance Currently in mass production Variety Product launch in 2009 Hybrid Product Launch in 2011 Rice Variety seed market, Rice Hybrid seed market,

Drought-FITTM


Single gene Japonica rice (GM) Four Generations Checked in Greenhouse Strip trials permission to RCGM, 2008 Large Scale Field Trail, 2009 Commercial Seed Production 2010 Launch of GM drought tolerant Transgenic Japonica rice, 2011 Estimated market for drought tolerant variety, 50 M USD

Drought-FITTM


Multi gene Indica Hybrid rice (GM) Generating T0’s, parent for hybrid 2008 Greenhouse trials, 2009 Hybrid Seed Production, 2010 Strip trials permission to RCGM, 2011 Large Scale Field Trail, 2012 Commercial Seed Production 2013 Launch of GM drought tolerant Transgenic Hybrid Indica rice, 2013 Estimated market for drought tolerant hybrids, over ~100 M USD

Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~ 2013

Hybrid-FITTM


Drought-FIT TM

Nutrition-FITTM

Hybrid-FITTM

High Anti oxidant Rice (Non GM): 2009 High Lycopene products: 2011

Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~ 2011 Multigene gene Indica rice (GM) ~ 2012

Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~2013

Product Pipeline | 3rd generation – SummarybioAgriculture

Atash SeedsbioAgriculture

CollaborationsbioAgriculture

Normal plasticNormal plastic

05/05

BioperceptTMBioperceptTM

BioperceptTM

bioAgriculture

The twenty first century will be defined as a “plastic age”.

Mankind uses more plastics than iron & steel.

Single use plastic bags are the single largest source of solid waste pollution in the world today. These bags float around and stay in our air, water and land for a thousand years. Often termed as “white pollution”, countries around the world have taken steps to control this problem.

In India and in the Middle East, Avesthagen's presence and its strategic relationship with Limagrain has enables us to taken steps to introduce BioperceptTM – fully biodegradable and compostable plastic bags.

Biopercept TM addressing a need

BioperceptTM

bioAgriculture

Science & Innovation Science & Innovation

Predictive, Preventive & Personalised Healthcare

Mission StatementScience & Innovation

Science & Innovation focus on Preventive, Predictive and Personalised Healthcare through Systems Biology

Science & Innovation is core to Avesthagen's business of science strategy, an integrated platform of biotechnology and bioinformatics delivering Innovation with Systems Biology.

Science & Innovation enables new product development and Partnership building.

Predictive, Preventive Predictive, Preventive & Personalised Healthcare & Personalised Healthcare

- Systems Biology

- Avestagenome Project TM

- Natural Product Drug Discovery

Biochemistry Systems Biology

One Size fits all drugs Personalized medicine

Aging Stem Cells Therapy

Therapeutics / Diagnostics Theranostics

Treating Sickness Preventing Sickness

Avesthagen leads global change

Food for survival Food for health

Fossil fuels Alternative Energy

Predictive, Preventive & Personalised Healthcare

Systems BiologyPredictive, Preventive & Personalised Healthcare

Confluence of Technology, Tools and Knowledge

penicillinssulphonamidesaspirin

psychotropics

NSAIDS

H2-antagonistsbeta blockers

lipid lowerersACE-inhibitors

Biotech drugs

chronicdegenerativedisease associatedwith ageing,inflammation,cancer

drugs againsttargets identifiedfrom disease genes

1900 20301950 1960 1970 1980 1990 2000 2010 2020 2040

New

The

rape

utic

Cyc

les

1st generation 2nd generation 3rd generation

natural productsand derivatives

serendipity

receptors

enzyme

genetic engineering

cell pharmacology/molecular biology

genomics/ proteomics

So

urc

e:

CM

S,

Le

hm

an

Bro

the

rs r

ese

arc

h

New Tools for Drug DiscoveryPredictive, Preventive & Personalised Healthcare

Diabetes Type 2: What’s Becoming Possible?

Avesthagen | Product Development StrategyFood – Pharma Convergence

Source : Burrill & Company

Biomarker Discovery

pDx + PVx + PRx*

2008 2010+ 2015+

- pDx + Fx - pDx + Rx


Clinically Validated Bioactives (Fx)

* Includes biopharmaceuticals and bioactives products

pDx + PVx + Rx

Predictive / Preventive (p)

bioNutrition

Personalized (P)

AVESTAGENOMEPredictive Diagnostics (pDx)

bioPharmaceuticals

Avesthagen | Product Development StrategyFood – Pharma Convergence


- Systems Biology

- The AvestagenomeTM Project


Overview

Predictive, Preventive and Personalized Healthcare:

A systems biology study of the Parsis to determine the genetic basis of longevity and age-related disorders.

The AvestagenomeTM Project

Ideal Population

The Parsis are well defined small population of less than 70,000 individuals in India

Concentrated in and around Mumbai Well documented genealogical charts demonstrating an

unbroken lineages for 30 generations Generations of marriage within the community has resulted in

increased positive traits - greater longevity diseases - Parkinson’s disease, stroke, heart disease, specific cancers, and Alzheimer’s disease.

Ideal population to study the interplay of multiple genes, environment and health factors

OverviewThe AvestagenomeTM Project

Market value of biomarker discovery

There are as many as 17 groups of diseases and wellness aspects in our project

Disease Market value

Cancer $35bn (Datamonitor report 2005-01-06)Arthritis $10bn (IMS health reports 2007)Diabetes $15bn (Leaddiscovery report 2006-03-27)

Other diseasesHeart diseases Thyroid DiseasesKidney Diseases Blood PressureLung Diseases Systemic Lupus ErythematosisMultiple Sclerosis Mental IllnessProstate Disease Gynecological ProblemsGenetic Disorders Neurological Disorders (Parkinson’s)Glucose-6-Phosphate Dehydrogenase Deficiency Asthma

Markets The AvestagenomeTM Project

Arthritis: Market and Opportunity

Disease Facts:

Poor prognosis leads to: - Aggressive treatment - Development of disease modifying antirehumatic drugs (DMARD)

Market needs:

- Arthritis Market value is $10bn

- There is a need to develop new strategies for Biomarker identification & nutritional products to prevent and/or treat Arthritis

IMS health reports 2007, Frost & Sullivan 2004 and Nature Reviews Drug Discovery 4, 11-12 (January 2005)


Markets | Age related conditions

Projected Alzheimer’s Disease Prevalence


Markets | Age related conditions

Distribution of cancer cases in Parsis and the general population of Mumbai, 2002-04.(Data obtained from the Bombay Cancer Registry, Mumbai)


Conditions | Cancers prevalence

Phase 1Systems Biology approach for Biomarker Discovery(eg. Osteoarthritis)

Archival

Biomarkers

HTS Genetic sequenceAnalysis (Genome, SNP etc.)

Gene ExpressionMicroarray

Metabolomics

Proteomics

Bioinformatics

Disease information

Strategy | R&DThe AvestagenomeTM Project

DNA and RNA Plasma & Serum Clinical & scientific Data

Blood collection

Phase 2Biomarkers to Drug Discovery

Biomarkers for Longevity - Preventive and Predictive Healthcare- Wellness and nutritional products

Disease Biomarkers - Personalized Healthcare

Validation of Biomarkers

Assay Development

Bioactive/Drug Screening

Nutritional/wellness products &

Drugs for Healthcare


Dis

ea

se

Bu

rde

n

Time

Co

st

1/r

ev

ers

ibil

ity

Typical Current

Intervention

Earliest Clinical

Detection

Earliest Molecular Detection

Initiating Events

Baseline Risk

Decision Support Tools:

Baseline Risk Preclinical Progression

Disease Initiation and Progression

Assess Risk Refine Assessment Predict/Diagnose Monitor Progression

Predict Events

Inform Therapeutics

Sources of New Biomarkers:

Stable Genomics:

SNPs Haplotype Mapping Gene Sequencing

Dynamic Genomics: Gene ExpressionProteomics Metabolomics

Therapeutic Decision Support


The Molecular Basis of Biological Processes

Alterations in Disease

New Targets for Dx, Rx, Vx

The Molecular Heterogeneity of Disease

Disease Subtypes

Right Rx forDisease

Individual Genetic Variation

Pharmaco-genetics

New Targets for Dx, Rx, Vx

DiseasePredisposition

PDxPRx

Analyzing the Molecular Profiles (Biosignatures) of Body Functions in Health and Disease


Study design

Database construction

Blood collection

Genotyping

Association Mapping

Sequenom Analysis

Transcriptome profiling

Metabolome

Plasma proteins

Stem Cells

Molecular Diagnostics

2007-08 2008-09 2009-10 2010-11 2011-12 2012-13

Avestagenome work flow for biomarker identification


Outcomes | HealthcareThe AvestagenomeTM Project

Source : Burrill & Company


Outcomes | Safer, More Effective Drugs

The same way that drugs work well for some people and not others, some people…

- Eat high fat diets and not show evidence of atherosclerosis. WHY?

- Have high cholesterol and not die of heart attacks. WHY?

Nutrigenomics

Outcomes | NutritionThe AvestagenomeTM Project

Outcomes | NutrigenomicsThe AvestagenomeTM Project

Source : Nature Publishing

Outcomes | NutrigenomicsThe AvestagenomeTM Project

Outcomes | Nutrition

The Avestagenome ProjectTo understand an individual’s response to nutrition through the analysis of their unique genetic make up

bioNutritionTo match an individual to his food and allows development of safe and effective dietary treatments


Blood Collection

Biomarkers Discovery

Biomarkers ValidationBiobank

Rx, Fx, Vx, Dx Development

Partner(s)

Avesthagen

Strategy | Business ModelThe AvestagenomeTM Project

Tie-up with Global players in Diagnostics, Vaccines, Pharma and Nutrition as well as Public bodies

Joint product optimization and development

Joint testing and validation with marketing partner

Partner responsible for marketing of product

Full IP ownership with Avesthagen

Commercial used of the outcomes to be based on Territories, Health Conditions and Uses/Products.

Avesthagen entitled to royalties and milestone payments / success fees

Production & Marketing

Diagnostics

Nutrigenomics Technology Partners

Strategy | CollaborationsThe AvestagenomeTM Project

Clinicals


- Systems Biology

- Avestagenome Project TM


Strategy | Screening of FFM bioactivesNatural Product Drug Discovery

Initial Bioactive Sample

Bioactive Concentrate

Pure Bioactive Compound

Novel Bioactive Compound

PotentialLead

Known Compounds

Structure Determination

Processing Experiments

Bio-assays guided Fractionation

Evaluation of “natural SAR”Shotgun synthesis of derivativesScale-up purification

Medicinal Chemistry

Development Track

Candidate

bioNutrition Science & Innovation

Strategy | Antarctica ProjectNatural Product Drug Discovery

What’s happening in Stem Cells?

Natural Product Drug Discovery

Strategy | Stem Cells

Human nerve stem cells transplanted into rats' damaged spinal cords have survived

Found: Stem Cells Responsible for Pancreatic Cancer

Mother's Stem Cells Passed to Baby—Suggests Possible Way to Treat Diabetes

Stem Cell Lines Generated from Amniotic Fluid

Multipotent Adult Progenitor Cells (MAPCs) Regenerate Blood in Mice

Treatments for Alzheimer’s and Multiple Sclerosis

Regeneration and repair of periphery nerves

Repair damaged heart muscle and improve cardiac function

Stem-cell transplantation for refractory or relapsing lymphomas

Research Programmes

Avesthagenome

Cancer

Cardiovascular

Hepatoxicity

Macular/Optic Nerve Regeneration

Red Blood Cells

Adult Stem Cells


Strategy | Stem Cells

“This mouse offers proof that researchers can create embryonic stem cells without using an egg. It grew from an embryo containing cells that had been reprogrammed to an embryonic state.”

Source: Whitehead Institute for Biomedical Research

Strategy | CapabilitiesNatural Product Drug Discovery

CHEMISTRY & ASSAYSMedicinal ChemistryAnalytical ChemistrySynthetic Chemistry

Computational ChemistryChemioinformatic

BioChemical AssaysCell Based Assays

Stem Cells (Screening)

CLINICAL & REGULATORYPreclinicals & Clinicals

Regulatory & Ethical approvals

BIOMARKERS & TARGETSStudy Design & Sample collection

Genotyping - SequencingTranscriptome (Gene Expression)

Metabolite IdentificationProteome ProfilingStatistical Analysis

Bioinformatics


Strategy | Business Model

CollaborationsDrug Discovery

FinancialsFinancials

Profit & LossAVESTHAGEN LIMITED

Funds RequirementAVESTHAGEN LIMITED

Avesthagen is a 650 employee company well-regarded worldwide for its uniqueness and leading position in India

Closure of Series-C early 2007 & IPO scheduled for 2008-2009

Product driven group and launch of new ones in 2007 across our businesses.

Strong and innovative IP portfolio with more than 151 inventions, 341 Patent applications and 100 applications on Copyrights & Trademarks

Profitable for three consecutive years (excl. exceptional items) with strong top line growth

Solid back-up from strategic and financial investors

Long-term commitments from partners / clients

Multiple top international certifications and awards

Significant infrastructure expansion

Strong management team

MilestonesAVESTHAGEN LIMITED

THANK YOU

avesthagen final

Documents